GMP factory sell Abaloparatide cas 247062-33-5 with DMF Abaloparatide peptide powder

Product Name: Abaloparatide

CAS Number: 247062-33-5

Synonyms: BA 058, BIM 44058, Tymlos

Molecular Formula: C₁₇₄H₃₀₀N₅₆O₄₉

Molecular Weight: 3960.59 g/mol

Sequence: H‑Ala‑Val‑Ser‑Glu‑His‑Gln‑Leu‑Leu‑His‑Asp‑Lys‑Gly‑Lys‑Ser‑Ile‑Gln‑Asp‑Leu‑Arg‑Arg‑Arg‑Glu‑Leu‑Leu‑Glu‑Lys‑Leu‑Leu‑N‑Me‑Ala‑Lys‑Leu‑His‑Thr‑Ala‑NH₂

Purity: ≥98.0% (HPLC) | ≥99.0% (Premium Grade)

Appearance: White to off‑white lyophilized powder

Solubility: Slightly soluble in water; soluble in aqueous buffers

Storage: Store at -20°C (sealed, desiccated) for long‑term stability; avoid repeated freeze‑thaw cycles

Grade: Pharmaceutical Grade / Research Grade (for laboratory use only; not for human or veterinary clinical use)

Abaloparatide is a synthetic 34‑amino‑acid peptide analog of human parathyroid hormone‑related protein (PTHrP 1‑34) and a potent, selective agonist of the parathyroid hormone type 1 receptor (PTH1R). It shares 41% homology with human PTH 1‑34 and PTHrP 1‑34, with identical receptor‑activating domains in the first 21 amino acids. As an osteoanabolic agent, it selectively activates PTH1R signaling (Gs/cAMP pathway and β‑arrestin recruitment) to stimulate osteoblast proliferation and bone formation, enhancing bone mineral density (BMD) and cortical bone structure.

• High Selectivity: Preferentially activates PTH1R with minimal off‑target effects, supporting targeted bone‑building activity.
• Strong Osteoanabolic Activity: Promotes de novo bone formation, increases trabecular and cortical bone mass, and reduces fracture risk in preclinical and clinical models.
• Consistent Purity: Manufactured via solid‑phase peptide synthesis (SPPS) with rigorous purification; HPLC‑validated purity ≥98% (≥99% for premium batches) ensures batch‑to‑batch consistency.
• Stable Formulation: Lyophilized powder format minimizes degradation; stable under recommended storage conditions for extended shelf life.
• Versatile Applications: Suitable for osteoporosis research, bone metabolism studies, drug development, and preclinical efficacy testing.

Abaloparatide binds to and activates PTH1R on osteoblasts and osteocytes, triggering intracellular signaling cascades that upregulate genes involved in osteoblast differentiation, collagen synthesis, and bone matrix mineralization. Unlike anti‑resorptive agents, it directly stimulates new bone growth, making it a first‑line anabolic therapy for osteoporosis in clinical development.

• Research Use: In vitro studies of PTH1R signaling, bone cell biology, and osteoporosis pathogenesis; in vivo animal models for evaluating bone formation, BMD changes, and fracture prevention.
• Drug Development: Lead compound for novel anabolic osteoporosis therapies; formulation development for injectable delivery systems.
• Biomedical Research: Investigations into calcium homeostasis, skeletal metabolism, and regenerative medicine applications.

• Purity: ≥98.0% by HPLC; premium grade ≥99.0%.
• Identity: Confirmed via mass spectrometry (MS) and amino acid analysis.
• Impurities: Residual solvents, heavy metals, and endotoxins meet international pharmaceutical standards (USP/EP).
• Peptide Content: ≥80.0% (calculated by amino acid analysis).
• Water Content: ≤8.0% (Karl Fischer titration).
• Acetate Content: 5.0%–12.0% (for acetate salt form).

• Available Sizes: 1 g, 5 g, 10 g, 25 g, 50 g, 100 g (custom sizes available upon request).
• Packaging: Sealed amber vials with butyl rubber stoppers; lyophilized under inert gas to preserve stability.
• Shipping: Shipped with ice packs (-20°C) for international delivery; cold‑chain logistics maintained to ensure product integrity.

This product is intended for research and development use only and is not approved for human or veterinary clinical applications. It is not for diagnostic, therapeutic, or household use. All handling and use must comply with local laboratory safety regulations and ethical guidelines.

• Manufacturing Expertise: Produced in GMP‑compliant facilities with strict quality control at every stage of synthesis and purification.
• Global Supply: Reliable bulk and small‑batch production capabilities to meet international research and pharmaceutical development demands.
• Technical Support: Comprehensive documentation (COA, HPLC, MS, amino acid analysis) available with every order; dedicated technical team for product inquiries.
• Customization: Custom peptide modifications, labeling (fluorescent, biotin), and formulation services available to support specific research needs.

For bulk inquiries, custom orders, or additional technical information, please contact our sales team.